Cartesian Therapeutics Inc
NASDAQ:RNAC
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
12.7
40.5
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one RNAC stock under the Base Case scenario is 9.13 USD. Compared to the current market price of 16.54 USD, Cartesian Therapeutics Inc is Overvalued by 45%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Cartesian Therapeutics Inc
Run backtest to discover the historical profit from buying and selling RNAC based on its intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Price Target |
Loading
|
Revenue Forecast |
|
Operating Income Forecast |
|
Earnings Forecast |
|
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Cartesian Therapeutics Inc
Balance Sheet Decomposition
Cartesian Therapeutics Inc
Current Assets | 124.8m |
Cash & Short-Term Investments | 87.2m |
Receivables | 35.5m |
Other Current Assets | 2m |
Non-Current Assets | 223m |
Long-Term Investments | 2m |
PP&E | 20.5m |
Intangibles | 198.8m |
Other Non-Current Assets | 1.7m |
Current Liabilities | 26.1m |
Accounts Payable | 2.9m |
Accrued Liabilities | 13.5m |
Other Current Liabilities | 9.8m |
Non-Current Liabilities | 423.1m |
Other Non-Current Liabilities | 423.1m |
Earnings Waterfall
Cartesian Therapeutics Inc
Revenue
|
54.1m
USD
|
Operating Expenses
|
-103.1m
USD
|
Operating Income
|
-49m
USD
|
Other Expenses
|
-184.9m
USD
|
Net Income
|
-233.9m
USD
|
Free Cash Flow Analysis
Cartesian Therapeutics Inc
USD | |
Free Cash Flow | USD |
RNAC Profitability Score
Profitability Due Diligence
Cartesian Therapeutics Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
Score
Cartesian Therapeutics Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
RNAC Solvency Score
Solvency Due Diligence
Cartesian Therapeutics Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Score
Cartesian Therapeutics Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RNAC Price Targets Summary
Cartesian Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for RNAC is 43.86 USD with a low forecast of 39.39 USD and a high forecast of 52.5 USD.
Shareholder Yield
Current shareholder yield for RNAC is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
RNAC Price
Cartesian Therapeutics Inc
Average Annual Return | 0.63% |
Standard Deviation of Annual Returns | 44.74% |
Max Drawdown | -92% |
Market Capitalization | 353.6m USD |
Shares Outstanding | 21 379 500 |
Percentage of Shares Shorted | 35.65% |
Ownership
RNAC Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts. The company went IPO on 2016-06-22. The Company’s lead asset, Descartes-08, is an RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) in Phase IIb clinical development for patients with generalized myasthenia gravis. Descartes-08 is designed to be an autologous anti-BCMA rCAR-T. Descartes-08 is in clinical development for autoimmune diseases, including Myasthenia gravis (MG), a chronic autoimmune disorder that causes disabling muscle weakness and fatigue. Its proprietary technology platform, RNA Armory, is designed to enable precision control and optimization of engineered cells for diverse cell therapies leveraging multiple modalities, including autologous, allogeneic, and in vivo transfection. Orphan Drug Designation by the United States Food and Drug Administration has granted Descartes-08 for the treatment of MG.
Contact
IPO
Employees
Officers
The intrinsic value of one RNAC stock under the Base Case scenario is 9.13 USD.
Compared to the current market price of 16.54 USD, Cartesian Therapeutics Inc is Overvalued by 45%.